F-18 fluorodeoxysorbitol for detecting response of bacterial infection to treatment

F-18 氟脱氧山梨醇用于检测细菌感染对治疗的反应

• 批准号: 10372094
• 负责人: CHIN K NG
• 金额: $ 23.45万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-16 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10372094
• 关键词: Antibiotic Resistance; Antibiotics; Bacteria; Bacterial Antibiotic Resistance; Bacterial Infections; Bacterial Pneumonia; Bioluminescence; Biopsy; Carbapenems; Categories; Ceftriaxone; Chemistry; Clinic; Clinical; Clinical Trials; Communicable Diseases; Development; Diagnosis; Discipline of Nuclear Medicine; Disease Progression; Double-Blind Method; Drug Kinetics; Drug resistance; Early treatment; Escherichia coli; Future; Genetic Materials; Goals; Gram-Negative Bacteria; Health; Hospitals; Human; Image; Imaging Device; Imaging Techniques; Imaging technology; Infection; Inflammation; Klebsiella; Klebsiella pneumoniae; Knowledge; Label; Leukocytes; Location; Lung; Lung infections; Magnetic Resonance Imaging; Methods; Microbe; Modeling; Monitor; Morbidity - disease rate; Multi-Drug Resistance; Mus; Outcome; Oxyquinoline; Patient imaging; Patients; Persons; Pharmaceutical Preparations; Pharmacotherapy; Physicians; Positron-Emission Tomography; Pre-Clinical Model; Prediction of Response to Therapy; Public Health; Publishing; Reporting; Research; Research Proposals; Rodent; Sensitivity and Specificity; Signal Transduction; Site; Source; Specialist; Speed; Sterility; Stress; Techniques; Testing; Thigh structure; Time; Treatment Cost; Treatment Efficacy; Treatment outcome; Triage; Work; X-Ray Computed Tomography; accurate diagnosis; antibiotic resistant infections; antimicrobial; base; carbapenem resistance; cellular imaging; clinically relevant; diagnostic platform; dosage; drug development; drug-sensitive; effective therapy; emerging pathogen; evidence base; fluorodeoxyglucose; imaging agent; improved; innovation; interest; microbial; mortality; mouse model; non-invasive imaging; novel; novel therapeutics; pathogen; pre-clinical; resistant Klebsiella pneumoniae; resistant strain; response; symposium; tool; treatment planning; treatment response; whole body imaging

Project summary (Abstract): Bacterial infections cause significant mortality and morbidity worldwide despite the availability of antibiotics. Antibiotic resistance is one of the most urgent threats to the public's health. Klebsiella microbes are gram- negative bacteria that have the inherent adaptive ability to resist treatment and also pass along genetic material that facilitates drug resistance in other bacteria. Klebsiella pneumoniae (Kp) infection has created a tremendous clinical problem for many hospitals worldwide. As of today, none of the current convention methods can provide early specific diagnosis and rapid monitoring of infections in the clinic. Consequently, treatment is often delayed or indefinite. The long-term goal is to develop a novel pathogen-specific and non-invasive whole-body imaging technique to guide patient management, monitor treatment efficacy, and speed drug development. The objective of this proposal is to validate F-18 fluorodeoxysorbitol (FDS) as an imaging tool for monitoring treatment efficacy and identifying drug resistant Kp from drug sensitive Kp. The central hypothesis is that FDS is a promising PET imaging agent with simple chemistry, optimal pharmacokinetics, and high specificity and sensitivity for predicting treatment response to bacterial infection. The rationale underlying this proposal is that its completion will contribute to accurate diagnosis for guiding effective treatment. The central hypothesis will be tested by pursuing two specific aims: 1) Identify the optimal imaging time of FDS for 2 drug-resistant and 2 drug- sensitive Kp strains in a clinically relevant preclinical mouse model of lung infection, 2) Determine the ability of FDS PET imaging to differentiate treatment response between drug-resistant Kp strains and drug-sensitive ones in mice of lung infection. We will pursue these aims by using novel and more clinically relevant Kp mouse models of lung infection and a double-blinded strategy to mimic actual clinical patient situation. The proposed studies are significant and innovative because FDS PET imaging can be validated to be a useful tool to triage drug options by predicting early treatment response to bacterial infection and thus avoiding the misuse and overuse of antibiotics. The results will have an important positive impact immediately in that they will establish an imaging technique for better understanding of bacterial infection, guiding patient management, and assisting drug development because they lay the groundwork to develop a suite of techniques for better treatment of Kp drug-resistant infections.

项目概述（摘要）：